Tags

Type your tag names separated by a space and hit enter

In vitro activity and post-antibiotic effects of linezolid in combination with fosfomycin against clinical isolates of Staphylococcus aureus.
Infect Drug Resist 2018; 11:2107-2115ID

Abstract

Objectives

Linezolid combination therapy is recommended for the treatment of Staphylococcus aureus (S. aureus) infections. However, the optimal regimen of the combination therapy for S. aureus is unknown. The objective of this study was to investigate the antibacterial activity, post-antibiotic effect (PAE), and post-antibiotic subminimum inhibitory concentration (MIC) effect (PA-SME) of linezolid alone and in combination with fosfomycin against eleven clinical isolates of S. aureus.

Methods

The synergistic effects and antibacterial activity of linezolid and fosfomycin were assessed by checkerboard and time-kill assays. To determine the PAE and PA-SME, S. aureus strains in the logarithmic phase of growth were exposed for 1, 2, and 3 hours to the antibiotics, alone and in combination. Recovery periods of test strains were evaluated using viable counting after dilution.

Results

Synergistic effects were observed for eight strains and no antagonism was found with any combination. Moreover, linezolid combined with fosfomycin at 4x MIC showed the best synergistic antibacterial effect, and this effect was retained after 24 hours. In addition, both the antibiotics alone and in combination showed increased PAE and PA-SME values in a concentration- and time-dependent manner.

Conclusion

Linezolid combined with fosfomycin exerted a good antibacterial effect against S. aureus, and the combinations have significant PAE and PA-SME.

Authors+Show Affiliations

Department of Pharmacy, The First Affiliated Hospital of Anhui Medical University, Hefei, Anhui, China. Department of Basic and Clinical Pharmacology, School of Pharmacy, Anhui Medical University, Hefei, Anhui, China, math2088@163.com. Anhui Institute of Innovative Drugs, School of Pharmacy, Anhui Medical University, Hefei, Anhui, China, math2088@163.com.Department of Basic and Clinical Pharmacology, School of Pharmacy, Anhui Medical University, Hefei, Anhui, China, math2088@163.com. Anhui Institute of Innovative Drugs, School of Pharmacy, Anhui Medical University, Hefei, Anhui, China, math2088@163.com.Department of Infectious Diseases, The First Affiliated Hospital of Anhui Medical University, Hefei, Anhui, China, lijiabin948@vip.sohu.com.Department of Basic and Clinical Pharmacology, School of Pharmacy, Anhui Medical University, Hefei, Anhui, China, math2088@163.com. Anhui Institute of Innovative Drugs, School of Pharmacy, Anhui Medical University, Hefei, Anhui, China, math2088@163.com.Department of Basic and Clinical Pharmacology, School of Pharmacy, Anhui Medical University, Hefei, Anhui, China, math2088@163.com. Anhui Institute of Innovative Drugs, School of Pharmacy, Anhui Medical University, Hefei, Anhui, China, math2088@163.com.Department of Basic and Clinical Pharmacology, School of Pharmacy, Anhui Medical University, Hefei, Anhui, China, math2088@163.com. Anhui Institute of Innovative Drugs, School of Pharmacy, Anhui Medical University, Hefei, Anhui, China, math2088@163.com.Department of Basic and Clinical Pharmacology, School of Pharmacy, Anhui Medical University, Hefei, Anhui, China, math2088@163.com. Anhui Institute of Innovative Drugs, School of Pharmacy, Anhui Medical University, Hefei, Anhui, China, math2088@163.com.Department of Basic and Clinical Pharmacology, School of Pharmacy, Anhui Medical University, Hefei, Anhui, China, math2088@163.com. Anhui Institute of Innovative Drugs, School of Pharmacy, Anhui Medical University, Hefei, Anhui, China, math2088@163.com.Department of Microbiology, Anhui Medical University, Hefei, Anhui, China.Department of Infectious Diseases, The First Affiliated Hospital of Anhui Medical University, Hefei, Anhui, China, lijiabin948@vip.sohu.com.Department of Basic and Clinical Pharmacology, School of Pharmacy, Anhui Medical University, Hefei, Anhui, China, math2088@163.com. Anhui Institute of Innovative Drugs, School of Pharmacy, Anhui Medical University, Hefei, Anhui, China, math2088@163.com.

Pub Type(s)

Journal Article

Language

eng

PubMed ID

30464553

Citation

Chen, Hao, et al. "In Vitro Activity and Post-antibiotic Effects of Linezolid in Combination With Fosfomycin Against Clinical Isolates of Staphylococcus Aureus." Infection and Drug Resistance, vol. 11, 2018, pp. 2107-2115.
Chen H, Li L, Liu Y, et al. In vitro activity and post-antibiotic effects of linezolid in combination with fosfomycin against clinical isolates of Staphylococcus aureus. Infect Drug Resist. 2018;11:2107-2115.
Chen, H., Li, L., Liu, Y., Wu, M., Xu, S., Zhang, G., ... Huang, X. (2018). In vitro activity and post-antibiotic effects of linezolid in combination with fosfomycin against clinical isolates of Staphylococcus aureus. Infection and Drug Resistance, 11, pp. 2107-2115. doi:10.2147/IDR.S175978.
Chen H, et al. In Vitro Activity and Post-antibiotic Effects of Linezolid in Combination With Fosfomycin Against Clinical Isolates of Staphylococcus Aureus. Infect Drug Resist. 2018;11:2107-2115. PubMed PMID: 30464553.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - In vitro activity and post-antibiotic effects of linezolid in combination with fosfomycin against clinical isolates of Staphylococcus aureus. AU - Chen,Hao, AU - Li,Lan, AU - Liu,Yanyan, AU - Wu,Maomao, AU - Xu,Shuangli, AU - Zhang,Guijun, AU - Qi,Caifen, AU - Du,Yan, AU - Wang,Mingli, AU - Li,Jiabin, AU - Huang,Xiaohui, Y1 - 2018/11/01/ PY - 2018/11/23/entrez PY - 2018/11/23/pubmed PY - 2018/11/23/medline KW - PA-SME KW - PAE KW - combination KW - fosfomycin KW - linezolid SP - 2107 EP - 2115 JF - Infection and drug resistance JO - Infect Drug Resist VL - 11 N2 - Objectives: Linezolid combination therapy is recommended for the treatment of Staphylococcus aureus (S. aureus) infections. However, the optimal regimen of the combination therapy for S. aureus is unknown. The objective of this study was to investigate the antibacterial activity, post-antibiotic effect (PAE), and post-antibiotic subminimum inhibitory concentration (MIC) effect (PA-SME) of linezolid alone and in combination with fosfomycin against eleven clinical isolates of S. aureus. Methods: The synergistic effects and antibacterial activity of linezolid and fosfomycin were assessed by checkerboard and time-kill assays. To determine the PAE and PA-SME, S. aureus strains in the logarithmic phase of growth were exposed for 1, 2, and 3 hours to the antibiotics, alone and in combination. Recovery periods of test strains were evaluated using viable counting after dilution. Results: Synergistic effects were observed for eight strains and no antagonism was found with any combination. Moreover, linezolid combined with fosfomycin at 4x MIC showed the best synergistic antibacterial effect, and this effect was retained after 24 hours. In addition, both the antibiotics alone and in combination showed increased PAE and PA-SME values in a concentration- and time-dependent manner. Conclusion: Linezolid combined with fosfomycin exerted a good antibacterial effect against S. aureus, and the combinations have significant PAE and PA-SME. SN - 1178-6973 UR - https://www.unboundmedicine.com/medline/citation/30464553/In_vitro_activity_and_post_antibiotic_effects_of_linezolid_in_combination_with_fosfomycin_against_clinical_isolates_of_Staphylococcus_aureus_ L2 - https://dx.doi.org/10.2147/IDR.S175978 DB - PRIME DP - Unbound Medicine ER -